Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients.

Advances in therapy - 1 Apr 2026

Girard Nicolas, Macouillard Pauline, Byng Danalyn, Meng Jie, Coerts Friso, Hunter Shannon, Struebing Alessandria, Xiong Yan, Park Sarah, Haq M Inaam, Tymejczyk Olga, Chouaid Christos, Audigier-Valette Clarisse, Debieuvre Didier, Quantin Xavier, Bosquet Lise, Pérol Maurice

Abstract excerpt

INTRODUCTION: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is a standard first-line (1L) treatment for advanced/metastatic EGFR non-small cell lung cancer (NSCLC). Despite improved overall survival (OS) and progression-free survival (PFS) compared to earlier generation TKIs, resistance and disease progression are common. No standardized second-line (2L) treatment exists for patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to France

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 41686417
DOI: 10.1007/s12325-025-03465-4
PMCID: PMC13065616

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients.PMID 41686417Read ↗

Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib.Semantic proximity Read ↗

Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.Semantic proximity Read ↗

Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data.Semantic proximity Read ↗

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)Semantic proximity Read ↗

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity Read ↗

A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study.Semantic proximity Read ↗

Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.Semantic proximity Read ↗

Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.Semantic proximity Read ↗

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy.Semantic proximity Read ↗

Outcomes of first-line osimertinib treatment for epidermal growth factor receptor-mutated non-small cell lung cancer in clinical practice settingsSemantic proximity Read ↗

Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.